A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 19 May 2017
At a glance
- Drugs Oliceridine (Primary) ; Moxifloxacin
- Indications Postoperative pain
- Focus Adverse reactions
- Sponsors Trevena
- 17 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jan 2015 New trial record